Nektar Therapeutics (NKTR)
The company now
Nektar Therapeutics is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in San Francisco, CA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $55 million and a loss of $164 million (its filed statements).
From its filings and filed figures; the desk's account of it is not written yet.
Where the revenue comes from
fiscal 2025, as filedRevenue by product, fiscal 2025
| Product | Fiscal 2025 | Fiscal 2024 | Share of revenue |
|---|---|---|---|
| Non Cash Royalty Revenue Related to Sale of Future Royalties | $54.9M | $64.3M | 99.5% |
| License Collaboration and Other Revenue | $300,000 | $597,000 | 0.5% |
As tagged in its annual report (Form 10-K, filed Mar 13, 2026 ↗), read from the SEC's financial statement data sets. The year before is the figure the record holds for the prior fiscal year.
The desk's written account of this company, its Past, Present and Future, is not on file yet.
How the company works
The desk has not read this company's annual report yet.
The record in brief
The desk has not written this company's report yet.